R&D refund delivers $1.123 million cash boost for PainChek
PainChek (ASX: PCK) has received a $1.123 million research and development (R&D) tax incentive refund relating to eligible FY2025 expenditure. The refund strengthens the Company’s cash position and supports continued investment in product development and commercialisation.
PainChek is the developer of the world’s first AI-powered pain assessment and monitoring application.
When big ASX news breaks, our subscribers know first
What the refund funded
The refund relates to R&D undertaken in support of PainChek’s core focus on advancing and commercialising its AI-enabled pain assessment platform. The eligible work spans both algorithm development and validation activities tied to the Company’s stated growth vectors.
Eligible activities included:
-
Continued development of the PainChek Adult algorithm
-
Continued development of the PainChek Infant algorithm
-
Validation activities supporting the Company’s entry into the US market
-
Expansion of the technology for use in children
These activities connect directly to two of PainChek’s priority areas: US expansion and paediatric use. The refund effectively reduces the net cost of the work already undertaken across both fronts.
Understanding the R&D Tax Incentive
The R&D Tax Incentive is an Australian Government programme that supports companies undertaking eligible R&D activities in Australia. Under the programme, eligible companies may receive a cash offset of up to 43.5% of qualifying R&D expenditure.
Why it matters for the investment case
The refund arrives against a backdrop of established commercial traction. PainChek is described as the world’s first regulatory-cleared medical device for the assessment of pain, and the first TGA-approved and FDA-cleared device of its kind.
The Company has attained regulatory clearance across multiple jurisdictions and operates a substantial installed base, providing context for the scale behind the funded R&D.
PainChek’s UK aged care expansion has run in parallel with its algorithm development work, with 4,000 new contracted licences secured in Q3 FY26 representing 9% quarter-on-quarter growth and adding $230,000 AUD in annual recurring revenue to the platform.
| Metric | Detail |
|---|---|
| R&D refund received | $1.123 million (FY2025) |
| Regulatory clearances | Australia, Canada, EU, New Zealand, Singapore, Malaysia, UK, and US (FDA De Novo clearance) |
| Aged care facility contracts | Over 2,000 |
| Digital pain assessments conducted | More than 20,000,000 |
The refund strengthens the Company’s cash position as it pursues its US rollout.
What comes next
The refund is intended to support continued investment in product development and commercialisation. Management’s stated focus areas remain US market entry and paediatric expansion, both of which featured in the eligible R&D work.
PainChek’s US market deployment strategy took a significant step forward with a Master Services Agreement signed with Sabra Health Care REIT, covering up to 20,000 beds across 329 North American facilities and establishing the REIT-funded model as a replicable template for institutional adoption.
The inflow signals continued forward investment. This announcement was approved for release by the Board.
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving healthcare announcement the moment it drops.